UCH-L5 (1q31.2) Ubikitiinin C-terminaalinen hydrolaasi (DUB perhettä)

UCH-L5 ( 1q31.2) ,

Ubiquitin C-terminal hydrolase L5

https://www.ncbi.nlm.nih.gov/gene/51377

Also known as  UCH37; CGI-70; INO80R; UCH-L5

Expression Ubiquitous expression in brain (RPKM 5.2), esophagus (RPKM 3.6) and 25 other tissues See more

Preferred Names

ubiquitin carboxyl-terminal hydrolase isozyme L5

Names

INO80 complex subunit R

ubiquitin C-terminal hydrolase UCH37

ubiquitin carboxyl-terminal esterase L5

ubiquitin carboxyl-terminal hydrolase L5

ubiquitin thioesterase L5

Related articles in PubMed

1. Positive cytoplasmic UCHL5 tumor expression in gastric cancer is linked to improved prognosis. Arpalahti L, et al. PLoS One, 2018. PMID 29474458, Free PMC Article
2. UCHL5 expression associates with improved survival in lymph-node-positive rectal cancer. Arpalahti L, et al. Tumour Biol, 2017 Jul. PMID 28681694
3. Nuclear ubiquitin C-terminal hydrolase L5 expression associates with increased patient survival in pancreatic ductal adenocarcinoma. Arpalahti L, et al. Tumour Biol, 2017 Jun. PMID 28653876
4. High expression of UCH37 is significantly associated with poor prognosis in human epithelial ovarian cancer. Wang L, et al. Tumour Biol, 2014 Nov. PMID 25123264
5. Expression and clinical significance of UCH37 in human esophageal squamous cell carcinoma. Chen Y, et al. Dig Dis Sci, 2012 Sep. PMID 22615012
   

See all (83) citations in PubMed
See citations in PubMed for homologs of this gene provided by HomoloGene

GeneRIFs: Gene References Into Functions

1. Our studies provide a molecular mechanism by which UCHL5 mitigates TGFbeta-1 signaling by stabilizing Smad2/Smad3. These data indicate that UCHL5 may contribute to the pathogenesis of idiopathic pulmonary fibrosis and may be a potential therapeutic target.
2. Positive cytoplasmic UCHL5 tumor immunoexpression is linked to increased survival of patients with small (<5 66="" a="" age="" and="" cancer="" cm="" disease="" gastric="" i-ii="" in="" is="" marker="" new="" older="" or="" p="0.037)." potential="" prognostic="" relevance.="" stages="" thus="" tumors="" uchl5="" with="" years="">
3. our report demonstrates significant value in targeting USP14/UCHL5 with VLX1570 in drug-resistant Waldenstrom macroglobulinemia (WM) and carries a high potential for clinical translation
4. UCHL5 is a promising novel prognostic marker in lymph-node-positive rectal cancer. Our results also advance the currently limited knowledge of biomarkers in colorectal cancer treatment.
5. UCHL5 expression could function as a prognostic marker in pancreatic ductal adenocarcinoma, particularly at disease stages IIB to III. As UCHL5 is one of the few markers predicting increased survival, our results may be of clinical relevance.
6. this work implicates hRpn13 and Uch37 in cell cycle progression, providing a rationale for their function in cellular proliferation and for the apoptotic effect of the hRpn13-targeting molecule RA190.
7. These results uncover a novel mechanism for E2F1 transcriptional activation through removal of its Lys-63-linked ubiquitination by UCH37.
8. Uch37 consists of two domains, a globular UCH-domain and a fibrous C-terminal tail. The C-terminal residues of Uch37 are implicated in Rpn13 binding.
9. Data indicate that ubiquitin thioesterase L5 UCH37 (UCHL5) comprises a catalytic UCH domain followed by the four-helix (alpha8-alpha11) C-terminal domain.
10. Data show that DEUBAD domain in RPN13 (ADRM1) activates ubiquitin thioesterase L5 (UCH-L5), and the related DEUBAD domain in INO80G (NFRKB) inhibits UCH-L5.
    

Peptide history, structure: Articles from Finland in the latest news (2018) . Also news about  pulmonary fibrosis (2018) . https://www.ncbi.nlm.nih.gov/protein/NP_001186190.1

Conserved Domains (1) summary

cd02255
Location:8 → 223

Peptidase_C12; Cysteine peptidase C12 contains ubiquitin carboxyl-terminal hydrolase (UCH) families L1, L3, L5 and BAP1

Peptide structure: History and some News:

REFERENCE   1  (residues 1 to 328)
  AUTHORS   Arpalahti L, Laitinen A, Hagstrom J, Mustonen H, Kokkola A,
            Bockelman C, Haglund C and Holmberg CI.
  TITLE     Positive cytoplasmic UCHL5 tumor expression in gastric cancer is
            linked to improved prognosis
  JOURNAL   PLoS ONE 13 (2), e0193125 (2018)
 AUTHORS   Arpalahti L, Hagstrom J, Mustonen H, Lundin M, Haglund C and
            Holmberg CI.
  TITLE     UCHL5 expression associates with improved survival in
            lymph-node-positive rectal cancer
  JOURNAL   Tumour Biol. 39 (7), 1010428317716078 (2017)
   PUBMED   28681694
  REMARK    GeneRIF: UCHL5 is a promising novel prognostic marker in
            lymph-node-positive rectal cancer. Our results also advance the
            currently limited knowledge of biomarkers in colorectal cancer
            treatment.
REFERENCE   3  (residues 1 to 328)
AUTHORS   Arpalahti L, Saukkonen K, Hagstrom J, Mustonen H, Seppanen H,
            Haglund C and Holmberg CI.
  TITLE     Nuclear ubiquitin C-terminal hydrolase L5 expression associates
            with increased patient survival in pancreatic ductal adenocarcinoma
  JOURNAL   Tumour Biol. 39 (6), 1010428317710411 (2017)

AUTHORS   Nan L, Jacko AM, Tan J, Wang D, Zhao J, Kass DJ, Ma H and Zhao Y.
  TITLE     Ubiquitin carboxyl-terminal hydrolase-L5 promotes TGFbeta-1
            signaling by de-ubiquitinating and stabilizing Smad2/Smad3 in
            pulmonary fibrosis
  JOURNAL   Sci Rep 6, 33116 (2016)
   PUBMED   27604640
  REMARK    GeneRIF: Our studies provide a molecular mechanism by which UCHL5
            mitigates TGFbeta-1 signaling by stabilizing Smad2/Smad3. These
            data indicate that UCHL5 may contribute to the pathogenesis of
            idiopathic pulmonary fibrosis and may be a potential therapeutic
            target.
ORIGIN      
        1 mtgnagewcl mesdpgvfte likgfgcrga qveeiwslep enfeklkpvh gliflfkwqp
       61 geepagsvvq dsrldtiffa kqvinnacat qaivsvllnc thqdvhlget lsefkefsqs
      121 fdaamkglal snsdvirqvh nsfarqqmfe fdtktsakee dafhfvsyvp vngrlyeldg
      181 lregpidlga cnqddwisav rpviekriqk ysegeirfnl maivsdrkmi yeqkiaelqr
      241 qlaeepmdtd qgnsmlsaiq sevaknqmli eeevqklkry kienirrkhn ylpfimellk
      301 tlaehqqlip lvekakekqn akkaqetk
//

http://www.biochemsoctrans.org/content/ppbiost/34/5/761/F1.large.jpg